Back to Results

A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)

Study category: Heart and Blood Conditions

Is this Study for You?

Let's Get Started!

Details
Age

Child

Type of Study

Treatment

Location

Childrens Hospital Colorado

Principal Investigator
Jessica Knight-Perry,  MD

Jessica Knight-Perry, MD

Study ID

Protocol Number: 20-2471

More information available at ClinicalTrials.gov: NCT04557735

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers